• Bufalin: From Steroid Scaffold to Target Validation

  2026-08-28

  Bufalin is a cardiotonic steroid with apoptosis-inducing, differentiation, and protein-degradation activities. This article presents an assay-centered framework for connecting Bufalin target engagement to mechanism in triple-negative breast cancer and hepatocellular carcinoma research.

• Bortezomib (PS-341) for Proteostasis Assays

  2026-08-28

  Bortezomib (PS-341) provides a reversible 20S proteasome perturbation for connecting proteostasis, cell death, and disease-model phenotypes. This guide translates its use into practical apoptosis, cancer, and TDP-43-related assay workflows while distinguishing established evidence from exploratory applications.

• 2-NBDG Glucose Uptake Assay Kit: Flux Context

  2026-08-28

  The 2-NBDG Glucose Uptake Assay Kit enables non-radioactive, single-cell analysis of glucose transport. This guide shows how to interpret uptake alongside ferroptosis and lipid-metabolism findings in sorafenib-resistant hepatocellular carcinoma without overstating what fluorescence alone can prove.

• GS-441524 Prodrug Pathways in Translational Research

  2026-08-27

  GS-441524 is more than a reference nucleoside: its translational value depends on activation, matrix-specific conversion, exposure, and analytical resolution. This article interprets recent LC–MS/MS evidence on GS-441524 prodrug pathways and translates it into practical guidance for antiviral, pharmacokinetic, and prodrug-development teams.

• Hyperoside, DHX9, and R-Loops in URSA

  2026-08-26

  This study identifies DHX9-mediated R-loop resolution as a mechanistic link between hyperoside treatment, reduced endometrial stromal cell senescence, and improved decidualization in unexplained recurrent spontaneous abortion. Its integrated human, mouse, and cellular design provides a useful framework for connecting genome-stability defects with reproductive outcomes while clarifying the limits of preclinical translation.

• CP-673451 in Cell Assay Workflows

  2026-08-26

  This scenario-driven guide explains how CP-673451 (SKU B2173) can improve interpretation of PDGFR-dependent viability, proliferation, cytotoxicity, and angiogenesis experiments. It combines product specifications with glioma literature to support solvent control, concentration selection, orthogonal validation, and practical vendor evaluation.

• Multi-Omics Maps ARID1A-Linked Melanoma Resistance

  2026-08-26

  The reference study integrates early signaling, molecular profiling, and network analysis to define how ARID1A loss rewires melanoma responses to BRAF/MAPK inhibition. Its identification of PRKD1, JUN, and NCK1 as resistance-associated nodes provides a framework for connecting adaptive signaling, immune visibility, and extracellular-matrix remodeling.

• EdU Flow Cytometry Assay Kits (Cy5) in Cancer Research

  2026-08-25

  Metabolic interventions can suppress tumor growth while simultaneously creating immune-evasion pressure. This thought-leadership analysis explains how EdU Flow Cytometry Assay Kits (Cy5) can turn that biological tension into a measurable S-phase endpoint for translational cancer research, using findings on serine/glycine restriction and PD-L1 lactylation as a strategic case study.

• VE-822 ATR Inhibitor: PDAC Research Workflow

  2026-08-24

  VE-822 is a potent ATR inhibitor for dissecting replication-stress signaling and testing combination strategies with gemcitabine or radiation. This practical guide connects DNA damage response inhibition with PDAC assay design, iPSC-informed model selection, dosing controls, and troubleshooting.

• Morin and the AMPD2 Energy Rescue Paradigm

  2026-08-24

  A translational perspective on how Morin connects AMPD2 activity, purine nucleotide cycling, mitochondrial dysfunction, and podocyte injury—while defining practical strategies for mechanism-first validation.

• SAG Protects Frataxin-Deficient Astrocytes

  2026-08-23

  Vicente-Acosta et al. showed that frataxin depletion drives mitochondrial dysfunction, reactive astrocyte features, inflammatory signaling, and neuron-toxic secreted effects in cultured human astrocytes. Chronic Smoothened receptor agonist treatment largely prevented these changes, identifying Hedgehog pathway activation as a potential strategy for modifying astrocyte-mediated neurodegeneration in Friedreich’s ataxia.

• Morin and the New Logic of Podocyte Energy Rescue

  2026-08-22

  Morin is emerging as more than a broadly active flavonoid: a mechanistically informative tool for connecting purine nucleotide cycling, mitochondrial energy failure, and podocyte injury. This thought-leadership perspective translates recent AMPD2 findings into practical guidance for disease-model design, compound handling, assay strategy, and translational decision-making.

• Ibrexafungerp Against Echinocandin-Resistant Candida

  2026-08-21

  This study evaluates ibrexafungerp, also known as MK 3118 or IBX, against 192 clinically derived Candida isolates with phenotypic or genotypic echinocandin resistance. By integrating EUCAST susceptibility testing, FKS hotspot genotyping, and wild-type upper-limit analysis, the authors show that activity is often retained but varies by Candida species and mutation position.

• Cycloheximide Workflows for Protein Turnover

  2026-08-20

  Cycloheximide provides acute control of eukaryotic translation for protein turnover studies, apoptosis assays, and mechanistic immune research. This workflow-focused guide shows how to separate synthesis effects from degradation, manage cytotoxicity, and extend findings from iron-dependent antiviral biology without overinterpreting global translation arrest.

• Polygodial: From TRPA1 Signal to Cell Phenotype

  2026-08-20

  Polygodial is a TRPA1 channel activator for connecting acute ion-channel activity with calcium-dependent epithelial and neuronal phenotypes. This article focuses on causal assay design, evidence interpretation, and the practical limits of translating TRPA1 responses across model systems.

8629 records 1/576 page Next 12345 下5页 Last page